Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Initial evidence with AD patients shows that a brain-penetrating ACE inhibitor counteracts the process of neurodegeneration and dementia.
|
30991105 |
2020 |
Presenile dementia
|
0.400 |
Biomarker
|
disease |
CTD_human |
We confirm 20 previous LOAD risk loci and identify five new genome-wide loci (IQCK, ACE, ADAM10, ADAMTS1, and WWOX), two of which (ADAM10, ACE) were identified in a recent genome-wide association (GWAS)-by-familial-proxy of Alzheimer's or dementia.
|
30820047 |
2019 |
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We confirm 20 previous LOAD risk loci and identify five new genome-wide loci (IQCK, ACE, ADAM10, ADAMTS1, and WWOX), two of which (ADAM10, ACE) were identified in a recent genome-wide association (GWAS)-by-familial-proxy of Alzheimer's or dementia.
|
30820047 |
2019 |
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
|
29034839 |
2018 |
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We used multivariable-adjusted Cox proportional hazard models to assess the association of gout with a new diagnosis of dementia (incident dementia), adjusting for potential confounders/covariates including demographics (age, race, sex), comorbidities (Charlson-Romano comorbidity index), and medications commonly used for cardiac diseases (statins, beta-blockers, diuretics, and angiotensin converting enzyme (ACE)-inhibitors) and gout (allopurinol and febuxostat).
|
30428833 |
2018 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that, ApoE ε4, ACE I and PON1-L55M T alleles are associated with dementia risk whether these polymorphisms were studied separately or gathered in haplotypes.
|
28657841 |
2018 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An additional aim was to examine the accuracy of the ACE-R to detect dementia and cognitive impairment no dementia (CIND).
|
28511735 |
2017 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study shows the relevance of polymorphisms in APOB (odds ratio (OR), 1.17; 95% confidence interval (95% CI), 0.74-1.85), APOC3 (OR, 1.33; 95% CI, 0.82-2.17) and APOE (OR, 1.75; 95% CI, 1.09-2.80), as genetic risk markers for hypercholesterolemia; polymorphisms in ACE (OR, 1.68; 95% CI, 0.32-8.77) and AGT (OR, 1.74; 95% CI, 0.97-3.14) for hypertension; and in APOE*3/*4 (OR, 2.06; 95% CI, 1.70-2.51) and APOE*4/*4 (OR, 3.08; 95% CI, 1.85-5.12) as unambiguous markers of dementia.
|
29081697 |
2017 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As previously found for rs1799752 in ACE, rs5186 in AGTR1 was associated with dementia at baseline (OR: 3.25 [CI: 1.42-7.06], z = 2.90, p = 0.004).
|
27639288 |
2017 |
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Other covariates in the model that were independently associated with CINA included advanced age, diabetes mellitus (DM), use of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), history of dementia and living in a residential care facility.
|
27038455 |
2017 |
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Addenbrooke's Cognitive Examination III (ACE-III), an adaptation of the ACE cognitive screening test, has been demonstrated to have high sensitivity and specificity in detecting cognitive impairment in patients with dementia and other neurological and psychiatric disorders.
|
28865943 |
2017 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We screened 37 AD, 8 mild cognitive impairment (MCI), 3 AD and CVD (cerebrovascular disease), 3 MCI and CVD, 8 frontotemporal dementia (FTD) and 2 progressive supranuclear palsy (PSP) patients, and 28 normal controls (NCs).We sequenced PSEN1, PSEN2 and APP (EOAD risk factors), as well as MAPT, GRN and TARDBP for all cases and NCs, and analysed the APOE, CLU, CR1 and PICALM genotypes as well as the MAPT and ACE haplotypes (LOAD risk factors) for the AD (n = 37) and AD + MCI (n = 45) cases and NCs (n = 28).We identified variants in PSEN1, PSEN2 and TARDBP across a range of phenotypes (AD, AD and CVD, FTD and PSP), suggesting that screening of all known candidate genes of Alzheimer's and non-Alzheimer's forms of dementias in all dementia cases might be warranted.
|
26159191 |
2015 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The frequency of the ACE*ins allele was also greater in the groups with Alzheimer's disease and dementia in general (P = 0.022; P = 0.045), but genotype frequencies were only different in groups without the E*4/-317*ins haplotype (P = 0.012 for Alzheimer's disease; P = 0.04 for dementia).
|
21533863 |
2011 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study suggests that the ACE I/D polymorphism does not have any genetic association with global or specific cognitive domain in aged men without dementia.
|
21833743 |
2011 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Variations among reports on the relationship between the ACE ID polymorphism and dementia may be due to lack of consideration for gene-gene and gene-phenotype associations.
|
18838196 |
2010 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Frequency of ACE D allele was seemingly high in dementia cases (26.7%) when compared to controls (11.2%).
|
19716217 |
2009 |
Presenile dementia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.
|
17192785 |
2007 |
Presenile dementia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
No difference in ACE levels was found between the dementia groups and controls.
|
17270454 |
2007 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The involvement of the ACE D/I polymorphism in the pathogenesis of DWMHs in dementia (AD and VaD), by a mechanism that is independent of its association with cardiovascular risk factors, should be confirmed in a large population-based sample.
|
16970648 |
2006 |
Presenile dementia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Alzheimer disease risk and genetic variation in ACE: a meta-analysis.
|
14872014 |
2004 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein E, angiotensin-converting enzyme and alpha-1-antichymotrypsin genotypes are not associated with post-stroke dementia.
|
12736093 |
2003 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was a lack of association between presence of the D allele on the ACE gene and dementia status.
|
12634288 |
2003 |
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paraoxonase, ACE, and MTHFR polymorphisms were not associated with VD or LOAD; these common polymorphisms might have a marginal role in the pathogenesis of dementia in older subjects.
|
11328206 |
2001 |
Presenile dementia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The angiotensin I converting enzyme gene as a susceptibility factor for dementia.
|
11402126 |
2001 |
Presenile dementia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, although inconsistent, several results of case-control studies tend to suggest that the ACE I/D genetic polymorphism may constitute a genetic susceptibility factor for dementia, reinforcing the hypothesis of a major implication of vascular risk factors in the occurrence of dementia.
|
10818534 |
2000 |